Industry Leader

Life science leaders must balance their need to apply AI technologies to improve patient care, and bottom lines — without getting caught-up in the AI hype machine.

Let’s face it … pitching potential investors is a remarkable opportunity. It could be your one shot at getting your idea or company off the ground, so you better be appealing, tantalizing, and even provocative.

Women who are starting life sciences companies often do not have access to a network of mentors and advisors, whose strong advocacy establishes instant credibility and opens the doors to investors.

Here are some examples of why “soft skills,” such as those related to relationship building, leadership, and communication, are essential to today’s pharma and biotech leaders.

Companies frequently talk about being patient-centric. But what I don’t hear discussed as often is the role of the patient after a drug is approved. And I am convinced it is equally important. Why? Because patients are not static; they grow and change over time.

Aside from the clinical opportunity that gene therapy products present; they do introduce tremendous complexity into both the manufacturing and commercial processes. Remember these three points before developing your gene therapy plan.

While the costs and reputational implications associated with pharma data breaches are enough to pay heed to cybersecurity, these compromises can pose a serious threat to patient safety.

Similar to a clinical trial setback, misclassification of independent contractors (ICs) can have a substantial negative impact on a pharma business.

Pharma companies that don’t emphasize risk management and insurance due diligence while adding exposures from new products or services to their policies will see the far-reaching impacts on their budgets.

New research confirms that many of the challenges sponsors face managing clinical trials stem from the disparate nature of processes and systems.